**Study of Pirtobrutinib for Blood Cancer Patients** This study is for people who have *Chronic Lymphocytic Leukemia (CLL)*, a type of blood cancer, or *Non-Hodgkin Lymphoma (NHL)*, another form of cancer affecting the lymph nodes. The purpose is to see if the medicine, **pirtobrutinib**, is safe and works well in the long run. Participants will come from a previous study called LOXO-BTK-18001. You can join this study if you are already a part of this earlier study and are either still taking the study medicine or are in a follow-up stage. You cannot join if you were in the very first part (Phase 1b) of the earlier study. **Key Points:** - The study will look at how safe and effective pirtobrutinib is over time. - Participants must already be enrolled in the earlier study, LOXO-BTK-18001. - You can't participate if you were in the first phase (Phase 1b) of the original study. If you meet these requirements, you might be able to continue receiving the medicine or continue with follow-up visits in this new study.